Takeshi Osonoi
Overview
Explore the profile of Takeshi Osonoi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
913
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sumida Y, Toyoda H, Yasuda S, Kimoto S, Sakamoto K, Nakade Y, et al.
J Atheroscler Thromb
. 2024 May;
31(11):1620-1633.
PMID: 38777770
Aim: No pharmacotherapeutic treatment has been established for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). This trial compared the effects of pemafibrate and omega-3-acid ethyl ester...
2.
Osonoi T, Oura T, Hirase T
Diabetes Obes Metab
. 2023 Oct;
26(1):126-134.
PMID: 37794628
Aim: To evaluate glycaemic control, body weight, and safety outcomes following treatment with tirzepatide or dulaglutide in patients with type 2 diabetes (T2D) with a baseline haemoglobin (HbA1c) level of...
3.
Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Nishida K, et al.
Diabetologia
. 2023 Sep;
66(12):2356-2367.
PMID: 37750893
Aims/hypothesis: Previous studies have suggested that glucose variability may accelerate atherosclerosis progression in people with type 2 diabetes. Current guidelines recommend assessing glycaemic control using continuous glucose monitoring (CGM), which...
4.
Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, et al.
Sci Rep
. 2023 Sep;
13(1):14649.
PMID: 37669959
We previously reported in the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A) that alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, attenuated the progression of carotid atherosclerosis in subjects...
5.
Osonoi T, Shirabe S, Saito M, Hosoya M, Watahiki N, Douguchi S, et al.
Diabetes Metab Syndr Obes
. 2023 Jun;
16:1799-1808.
PMID: 37363130
Purpose: In this study, we examined the effects of dapagliflozin on changes in hematopoiesis, iron metabolism, and body composition indices in elderly type 2 diabetic patients with renal impairment and...
6.
Osonoi T, Shirabe S, Saito M, Hosoya M, Douguchi S, Ofuchi K, et al.
Front Pharmacol
. 2023 Jun;
14:1205021.
PMID: 37351507
Imeglimin is a novel type 2 diabetes (T2D) drug that is expected to improve mitochondrial function. In its phase 3 clinical trials in Japanese patients with T2D, the hemoglobin A1c...
7.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al.
Cardiovasc Diabetol
. 2023 Jun;
22(1):143.
PMID: 37349722
Background: This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes...
8.
Osonoi T, Saito M, Hosoya M, Douguchi S, Ofuchi K, Katoh M
Front Endocrinol (Lausanne)
. 2023 Jan;
13:1042061.
PMID: 36714585
Background: Dotinurad is a novel uricosuric drug in Japan with selective and potent urate transporter 1 (URAT1) inhibitory activity. This study aims to evaluate the efficacy and safety of dotinurad...
9.
Rossing P, Garweg J, Anker S, Osonoi T, Pitt B, Rosas S, et al.
Diabetes Obes Metab
. 2022 Nov;
25(3):894-898.
PMID: 36331803
No abstract available.
10.
Yoshii H, Mita T, Katakami N, Okada Y, Osonoi T, Aso K, et al.
J Clin Endocrinol Metab
. 2022 Jul;
107(10):e3990-e4003.
PMID: 35908248
Context: Current guidelines recommend assessing glycemic control using continuous glucose monitoring (CGM) and hemoglobin A1c (HbA1c) measurement. Objective: This study aimed to clarify the characteristics of patients who might benefit...